News
TYRA
21.45
-1.42%
-0.31
Weekly Report: what happened at TYRA last week (0921-0925)?
Weekly Report · 15h ago
Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Madrigal Pharmaceuticals (MDGL)
TipRanks · 4d ago
Is Tyra Biosciences (TYRA) Undervalued As Phase 2 Data And Fresh Funding Reset Expectations?
Simply Wall St · 5d ago
Climb Bio added to ‘Analysts Current Favorites’ at Raymond James
TipRanks · 5d ago
Tyra Biosciences Price Target Cut to $40.00/Share From $50.00 by Oppenheimer
Dow Jones · 6d ago
Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40
Benzinga · 6d ago
Tyra Biosciences price target lowered to $40 from $50 at Oppenheimer
TipRanks · 6d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiol Therapeutics (CRDL), Tyra Bioscience (TYRA) and Alibaba Health Information Technology (OtherALBHF)
TipRanks · 6d ago
Tyra Biosciences Price Target Cut to $29.00/Share From $30.00 by HC Wainwright & Co.
Dow Jones · 6d ago
Tyra Biosciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $29
Benzinga · 6d ago
Tyra Biosciences price target lowered to $29 from $30 at H.C. Wainwright
TipRanks · 6d ago
Weekly Report: what happened at TYRA last week (0914-0918)?
Weekly Report · 09/21 09:58
Tyra Biosciences (TYRA) Stock May Stay Pricey Following Mixed Trial Data
Simply Wall St · 09/16 06:22
Tyra Bioscience announces $400M equity financing offering
TipRanks · 09/15 10:38
Stock Market Today: S&P 500, Dow and Nasdaq Futures Face Pressure as Brent Nears $108 and FOMC Commences Two-Day Meet— MSTR, CRWD, BMM in Focus
Benzinga · 09/15 09:33
Crude Oil Jumps 3%; Corning Shares Move Lower
Benzinga · 09/14 16:09
Elmet Group, Rum Group, Tyra Biosciences And Other Big Stocks Moving Higher On Monday
Benzinga · 09/14 15:01
Tyra Biosciences Shares Rise After $400 Million Offering Prices
Dow Jones · 09/14 14:30
Tyra Prices $400 Mln Underwritten Offering Of Stock & Warrants To Advance Dabogratinib 3x3
NASDAQ · 09/14 13:24
More
Webull provides a variety of real-time TYRA stock news. You can receive the latest news about Tyra Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).